Overactive bladder- Pipeline Insight, 2024

Overactive bladder- Pipeline Insight, 2024

DelveInsight’s, “Overactive Bladder- Pipeline Insight, 2024” report provides comprehensive insights about 15+companies and 15+pipeline drugs in Overactive Bladder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Overactive Bladder: Understanding

Overactive Bladder: Overview

Overactive bladder (OAB) is the name for a group of urinary symptoms. It is not a disease. The most common symptom is a sudden, uncontrolled need or urge to urinate. Some people will leak urine when they feel this urge. Another symptom is the need to pass urine many times during the day and night. OAB is basically the feeling that you’ve “gotta’ go” to the bathroom urgently and too much.

As many as 30 percent of men and 40 percent of women in the United States live with OAB symptoms. Many people living with OAB don't ask for help. They may feel embarrassed. Many people either don't know how to talk with their health care provider about their symptoms, or they think there aren't treatments that can help.

Risk Factors for OAB

• Neurologic disorders or damage to the signals between your brain and bladder
• Hormone changes
• Pelvic muscle weakness or spasms
• A urinary tract infection
• Side effects from a medication
• Diseases that affect the brain or spinal cord, like stroke and multiple sclerosis

Diagnosis

• Urinalysis: A urinalysis (urine test) examines the visual, chemical and microscopic aspects of your pee. A provider will look for red blood cells, white blood cells and bacteria. If you have any of them in your pee sample, you may have an infection that causes OAB.
• Urodynamic testing: Urodynamic tests measure how much pee remains in your bladder after you go to the bathroom, how much you pee, how fast you pee and how much pressure is on your bladder as it fills with pee.
• Ultrasound: An ultrasound is a noninvasive imaging test that allows a healthcare provider to take a detailed look at your bladder.
• Computed tomography (CT) scan: A CT scan is a noninvasive imaging test that produces 3D images of your bladder.
• Cystoscopy: A healthcare provider will use a special instrument (cystoscope) to look inside your bladder from your urethra. The provider typically uses a numbing gel so you don’t feel pain in your urethra. In rare cases, they may use general anesthesia, so you aren’t awake, won’t move and won’t feel any pain.

Treatment

There are a number of things you can do to manage OAB. Everyone has a different experience with what works best.

 Lifestyle Changes

 Medical and Surgical Treatments

 Prescription Drugs

 Bladder Botox® (botulinum toxin) Treatments

 Nerve Stimulation (peripheral and central)

 Surgery

 Bladder training is the main treatment. This can work well in up to half of cases.

 Medication may be advised instead of, or in addition to, bladder training.

 Pelvic floor exercises may also be advised in some cases.

""Overactive Bladder- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Overactive Bladder pipeline landscape is provided which includes the disease overview and Overactive Bladder treatment guidelines. The assessment part of the report embraces, in depth Overactive Bladder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Overactive Bladder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Overactive Bladder R&D. The therapies under development are focused on novel approaches to treat/improve Overactive Bladder.

Overactive Bladder Emerging Drugs Chapters

This segment of the Overactive Bladder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Overactive Bladder Emerging Drugs

Neuronox: AbbVie/Medytox

Neuronox, an acetylcholine inhibitor is being developed by Medy-Tox for the treatment of the Overactive Bladder. The active ingredients involve Clostridium botulinum toxin type A. It is currently in the phase III stage of development. In September 2020, US drugmaker Allergan entered into a license agreement with South Korea’s Medytox under the terms of which, on closing, Allergan would pay Medytox an upfront of USD 65 million and Medytox would grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialise certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. In May 2020, AbbVie announced that it had finished its acquisition of Allergan plc following receipt of regulatory approval from all government authorities needed by the transaction agreement and approval by the Irish High Court.

URO-902: Urovant Sciences

Urovant Sciences is developing URO-902 for the treatment of the Overactive Bladder. URO-902 has the potential to be the first gene therapy for OAB patients. This innovative treatment has the capability to tackle an unmet need for patients who have failed oral pharmacologic therapies and are concerned with potential urinary retention or surgical interventions pertinent to existing third-line OAB treatments. It is currently in the phase II stage of development.

Further product details are provided in the report……..

Overactive Bladder: Therapeutic Assessment

This segment of the report provides insights about the different Overactive Bladder drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Overactive Bladder

There are approx. 15+key companies which are developing the therapies for Overactive Bladder. The companies which have their Overactive Bladder drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

Phases

DelveInsight’s report covers around 15+products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Overactive Bladder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Overactive Bladder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Overactive Bladder drugs.

Overactive Bladder Report Insights

• Overactive Bladder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Overactive Bladder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Overactive Bladder drugs?
• How many Overactive Bladder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Overactive Bladder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Overactive Bladder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Overactive Bladder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Dong-A ST Co., Ltd.
• AbbVie/Medytox
• Urovant Sciences
• Taiho Pharma
• Velicept Therapeutics

Key Products

• DA-8010
• Neuronox
• URO-902
• TAC-302
• Solabegron